Hot Investor Mandate: USA-Based Investment Firm Seeks Pre-Seed and Seed Opportunities in the Intersection of Healthcare and Technology

27 Apr

A venture capital firm founded in 2018 with headquarters in the US closed an initial fund of $20M USD dedicated to early-stage life science ventures from Pre-seed to Seed. The initial size of investment ranges from $250k-1M. The firm partners with companies in the US, Canada, UK, and Israel.

The firm is interested in companies under a $50M valuation cap. The firm acts as a co-investor and will not require board seating.

The firm is interested in deep health-tech. The firm is opportunistic and will consider pre-FDA companies in development and clinical phases. The firm is not interested in traditional pharmaceuticals, diagnostics, or health information technologies.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm in Canada Actively Invests in Digital Health, Open to Medical Devices and Diagnostics With Digital Component, Investing Up to $5M

27 Apr

A venture capital firm headquartered in Canada was co-founded by a physician who previously co-founded a successful private equity firm. The firm is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD 0.5 million and USD 5 million. The firm is currently operating out of its second fund. The firm participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel.

The firm is primarily interested in investing in companies in the digital health sector but will also consider the medical and diagnostic devices sectors that have a digital component to them. The firm is open to all modalities within the digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in development as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology to be revenue generating.

The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat as determined by check size on a case-by-case basis. The firm will participate both as a lead and co-investor.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Firm With USA Headquarters Invests in Technologies Leveraging Biology, Technology, and Data Science, Mainly in Seed to Series A

27 Apr

A venture capital firm founded in 2018 and is based in the US invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.

The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, is not interested in traditional medical devices or digital health.

The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The Innovator’s Pitch Challenge – Applications Due Tomorrow!

20 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

The Innovator’s Pitch Challenge (IPC) is a highlight of the Redefining Early Stage Investment (RESI) conferences! Innovative startups in life science and healthcare showcase their technology by pitching to investors in a live Q&A format, providing feedback, practice, and, sometimes, valuable connections that lead to deals. All finalists are divided into separate IPC sessions based on similar sectors and technologies. This allows relevant investors and industry professionals with field expertise to provide targeted questions and feedback. IPC participation also includes a space to exhibit a posterboard highlighting their product or technology in a large exhibit hall for the full day of the conference. With the live Q&A session and poster exhibit, companies are able to boost their exposure and increase their chances of networking with relevant investors and strategic partners.

2022_0921_RESIBoston_007-800x534Pitch & Investor Q&A

2022_0921_RESIBoston_001s-800x534IPC Poster

Over 30 companies have been confirmed to pitch at RESI Boston on June 5 and there is one day left to apply until the deadline of tomorrow, Friday, April 21.

If you are involved with an early-stage life science company, actively fundraising, and want to boost your exposure, gain valuable feedback from investors and industry experts, and secure meetings with investors who have a genuine interest in your technology, apply today!

Below is a list of companies who have been accepted as finalists for RESI Boston, June 5-7. In-person conference attendees will be provided with “RESI Cash” that can be used to vote for their favorite pitch.

Featured Pitch Companies

ipc-end-bANNER -2RESI-Boston-2023-June-1100px

How Tech Hubs Can Get Involved at RESI Boston, June 5-7

20 Apr

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

RESI Boston, June 5-7 will be in-person on June 5, followed by two days of virtual partnering on June 6-7. If you are part of a tech hub, Life Science Nation (LSN)’s Redefining Early Stage Investment (RESI) conference series is a great place for companies in the earliest stages of the life science industry to connect with potential investors. An integral part of RESI is the global tech hub ecosystem of accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations.

Through RESI, tech hub affiliated startups gain access to resources beyond partnering with investors and strategic partners. Resources such as the LSN Investor Database, Innovator’s Pitch Challenge (IPC), free workshops, and Entrepreneurial Courses. These tools help develop compelling marketing materials, build meaningful relationships with investors and secure necessary early-stage funding.

At RESI Boston, June 5-7, tech hub organizations and their startups can utilize:

  • Super Early Bird Registration Rates for full conference or virtual only registrations (startup must be from LSN’s tech hub partners)
  • Complimentary tech hub staff registration
  • 50% off sponsorship opportunities
  • Free second attendee registration for Innovator’s Pitch Challenge (IPC) participants

Life Science Nation will host a free webinar, How Tech Hubs Can Get Involved at RESI Boston, on Wednesday, May 3rd at 12:00PM ET. Register here.

This free webinar is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, regional organizations, and more who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startups who’ve raised less than $2M USD in capital expand their outreach from Regional to Global, build a target list of investors, get involved with the RESI conference series, and more. This webinar will be hosted by Erika Wu, BD Manager of Global Tech Hubs.

FREE_TECH-HUB-WEBINAR_Banner

For more information, please contact Erika Wu, Business Development Manager, Global Tech Hubs of LSN.

RESI-Boston-2023-June-1100px

Connect with 300+ Innovative Life Science Startups at RESI Boston Conference

20 Apr

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Are you representing a service provider, big pharma/medtech, or investor looking to connect with innovative life science startups? Don’t miss the upcoming RESI Boston Conference from June 5-7! With over 300 startups from the therapeutics, medical devices, diagnostics, and digital health/healthcare IT sectors expected to attend, this event provides the perfect opportunity to find your next strategic partner or investment opportunity.

As a registered attendee, you’ll have access to a range of networking opportunities, including 1-1 Partnering Meetings. This efficient system allows you to schedule meetings with startups based on a fit of sector, indication and phase of development.

You can also participate in the Innovator’s Pitch Challenge, where you can hear from some of the most promising startups in the industry as they pitch their ideas to seek licensing opportunities and early-stage funding. This is a great way to get a quick overview of what’s new and exciting in the space.

In addition to these opportunities, RESI Boston also offers sponsored workshops and exhibition spaces, where you can showcase your existing programs, products and services, gaining extra exposure from peers and experts.

Check out RESI Sponsorship Brochure

Don’t miss out on this incredible opportunity to connect with cutting-edge startups and gain valuable industry insights. Register for RESI Boston today and take the first step towards building the future of the life sciences industry.

Check out the RESI Boston June 2023 Featured Startups* below:

*As of April 18, 2023

cs4202023

RESI-Boston-2023-June-1100px

Hot Investor Mandate: Investment Arm of Non-Profit Organization Focuses on Life Science Technologies Targeting Blood Diseases, Infectious Diseases, and More

20 Apr

A venture arm of a non-profit organization with offices in the US closed an initial fund of $50M USD dedicated to early-stage life science ventures from Series A to C. The initial size of investment ranges from $250k-2M and the firm aims to invest in 10 companies in the upcoming year. The firm prefers to invest in US-based companies but is open to global opportunities.

The firm is niched on four key areas of focus: benign hematology, transfusion medicine, cell therapy, and infectious diseases. The firm will consider therapeutics, diagnostics, and medical devices. The firm will consider therapeutics of all modalities from Pre-Clinical to Phase II. Within diagnostics, the firm is opportunistic and looks at technologies in clinical phases or on the market (must include proof of concept). Within medical devices, the firm is open to all technologies, but is more interested in cell therapy-enabling technologies in clinical phases or on the market (must include proof of concept). Focused on the need for blood-related and cellular technologies, the firm is interested in making not only a financial, but humanitarian investments that also tie back to the parent company.

The firm highly values working with a management team that is 100% committed to the project. The firm prefers that the team has an even distribution of members with scientific and commercial expertise. The firm is a strategic co-investor and seeks to work with the respective knowledge experts on the team.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →